MC
MPM Capital
MPM Capital is a Series A to Series D stage investment firm. It has made 11 investments, with focus areas including Biotech & Life Sciences, Healthcare. 73% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (55% of deals). Average disclosed round size is $73.7M (across 10 rounds with reported amounts).
Portfolio
11
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
AG
Ansbert Gadicke
Co-Founder and Managing Director
Tony Rosenberg
Executive Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Umoja Biopharma | Series C | $100M | Jan 2025 |
 AstronauTx Ltd. | Series A | $61M | Oct 2023 |
 Aktis Oncology | Series A | $84M | Aug 2022 |
 CODA Biotherapeutics | Series B | $28M | Dec 2021 |
 Protego Biopharma | Series A | $51M | Nov 2021 |
 Orna Therapeutics | Series A | $80M | Feb 2021 |
| EElevateBio | Series B | $170M | Mar 2020 |
 Werewolf Therapeutics | Series A | $56M | Nov 2019 |
| SSiO2 Medical Products | Unknown | — | Nov 2019 |
 Frontier Medicines | Series A | $67M | Jun 2019 |
 TriNetX | Series D | $40M | Mar 2019 |
Top Co-Investors
F2 Venture Capital3 shared
Deerfield2 shared
DCVC Bio2 shared
Novartis Venture Fund2 shared
Merck Global Health Innovation Fund1 shared
RA Capital Management1 shared
Versant Ventures1 shared
Silicon Valley Bank1 shared
Double Point Ventures1 shared
ARK Invest1 shared
Cormorant Asset Management1 shared
Qiming Venture Partners USA1 shared
RTW Investments1 shared
Alexandria Venture Investments1 shared
SoftBank Vision Fund1 shared
CaaS Capital1 shared
K2 HealthVentures1 shared
Dementia Discovery Fund1 shared
Bristol Myers Squibb1 shared
EQT Life Sciences1 shared
Last updated: 6 March 2026